These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 8397766)
41. Monoclonal antibodies in the treatment of lung cancer. Egri G; Takáts A Eur J Surg Oncol; 2006 May; 32(4):385-94. PubMed ID: 16504454 [TBL] [Abstract][Full Text] [Related]
42. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related]
43. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins. Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669 [TBL] [Abstract][Full Text] [Related]
44. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY; Marasco WA Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024 [TBL] [Abstract][Full Text] [Related]
45. Current status of antitumor therapy with monoclonal antibodies. Scheinberg DA; Houghton AN Oncology (Williston Park); 1987 May; 1(3):31-40. PubMed ID: 3079479 [TBL] [Abstract][Full Text] [Related]
46. Immunotoxin therapy of malignant melanoma. Spitler LE Med Oncol Tumor Pharmacother; 1986; 3(3-4):147-52. PubMed ID: 3543527 [TBL] [Abstract][Full Text] [Related]
47. Recombinant antibodies in cancer therapy. Nayeem MS; Khan RH Curr Protein Pept Sci; 2006 Apr; 7(2):165-70. PubMed ID: 16611141 [TBL] [Abstract][Full Text] [Related]
48. Immunotoxin: A new tool for cancer therapy. Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037 [TBL] [Abstract][Full Text] [Related]
49. Recombinant immunotoxins in targeted cancer cell therapy. Reiter Y Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597 [TBL] [Abstract][Full Text] [Related]
51. Enhancement of immunotoxin activity using chemical and biological reagents. Wu M Br J Cancer; 1997; 75(9):1347-55. PubMed ID: 9155057 [TBL] [Abstract][Full Text] [Related]
52. Immunotoxins: an update. Thrush GR; Lark LR; Clinchy BC; Vitetta ES Annu Rev Immunol; 1996; 14():49-71. PubMed ID: 8717507 [TBL] [Abstract][Full Text] [Related]
57. Cytotoxic immune responses mediated by monoclonal antibodies in MS: incorrectly dismissed as ineffective? Killestein J; Polman CH Int MS J; 2007 Jun; 14(2):39-40. PubMed ID: 17686340 [No Abstract] [Full Text] [Related]
58. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. Frankel AE; FitzGerald D; Siegall C; Press OW Cancer Res; 1996 Feb; 56(4):926-32. PubMed ID: 8631036 [No Abstract] [Full Text] [Related]
59. Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I; Trail P; Siegall C; Firestone R; Hellström KE Cancer Chemother Pharmacol; 1996; 38 Suppl():S35-6. PubMed ID: 8765413 [No Abstract] [Full Text] [Related]
60. Immunotoxin therapy for CNS tumor. Rustamzadeh E; Low WC; Vallera DA; Hall WA J Neurooncol; 2003; 64(1-2):101-16. PubMed ID: 12952291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]